EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Molecular features of the serological IgG repertoire elicited by egg-based, cell-based, or recombinant haemagglutinin-based seasonal influenza vaccines: a comparative, prospective, observational cohort study

Juyeon Park, Foteini Bartzoka, Troy von Beck, Zhu-Nan Li, Margarita Mishina, Luke S Hebert, Jessica Kain, Feng Liu, Suresh Sharma, Weiping Cao, Devon J Eddins, Amrita Kumar und 22 weitere

The Lancet Microbe · 2025-02 · 6 (2) · 100935

DOI: 10.1016/j.lanmic.2024.06.002 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Lancet Microbe, 2025-02. Verfasst von Juyeon Park und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA; Department of Chemical Engineering, The University of Texas …. Hauptthemen laut MEDLINE: Influenza Vaccines, Antibodies, Viral, Influenza, Human, Immunoglobulin G. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, Gates Foundation, CDC HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Egg-based inactivated quadrivalent seasonal influenza vaccine (eIIV4), cell culture-based inactivated quadrivalent seasonal influenza vaccine (ccIIV4), and recombinant haemagglutinin (HA)-based quadrivalent seasonal influenza vaccine (RIV4) have been licensed for use in the USA. In this study, we used antigen-specific serum proteomics analysis to assess how the molecular composition and qualities of the serological antibody repertoires differ after seasonal influenza immunisation by each of the three vaccines and how different vaccination platforms affect the HA binding affinity and breadth of the serum antibodies that comprise the polyclonal response. METHODS: In this comparative, prospective, observational cohort study, we included female US health-care personnel (mean age 47·6 years [SD 8]) who received a single dose of RIV4, eIIV4, or ccIIV4 during the 2018-19 influenza season at Baylor Scott & White Health (Temple, TX, USA). Eligible individuals were selected based on comparable day 28 serum microneutralisation titres and similar vaccination history. Laboratory investigators were blinded to assignment until testing was completed. The preplanned exploratory endpoints were assessed by deconvoluting the serological repertoire specific to A/Singapore/INFIMH-16-0019/2016 (H3N2) HA before (day 0) and after (day 28) immunisation using bottom-up liquid chromatography-mass spectrometry proteomics (referred to as Ig-Seq) and natively paired variable heavy chain-variable light chain high-throughput B-cell receptor sequencing (referred to as BCR-Seq). Features of the antigen-specific serological repertoire at day 0 and day 28 for the three vaccine groups were compared. Antibodies identified with high confidence in sera were recombinantly expressed and characterised in depth to determine the binding affinity and breadth to time-ordered H3 HA proteins. FINDINGS: During September and October of the 2018-19 influenza season, 15 individuals were recruited and assigned to receive RIV4 (n=5), eIIV4 (n=5), or ccIIV4 (n=5). For all three cohorts, the serum antibody repertoire was dominated by back-boosted antibody lineages (median 98% [95% CI 88-99]) that were present in the serum before vaccination. Although vaccine platform-dependent differences were not evident in the repertoire diversity, somatic hypermutation, or heavy chain complementarity determining region 3 biochemical features, antibodies boosted by RIV4 showed substantially higher binding affinity to the vaccine H3/HA (median half-maximal effective concentration [EC50] to A/Singapore/INFIMH-16-0019/2016 HA: 0·037 μg/mL [95% CI 0·012-0·12] for RIV4; 4·43 μg/mL [0·030-100·0] for eIIV4; and 18·50 μg/mL [0·99-100·0] μg/mL for ccIIV4) and also the HAs from contemporary H3N2 strains than did those elicited by eIIV4 or ccIIV4 (median EC50 to A/Texas/50/2012 HA: 0·037 μg/mL [0·017-0·32] for RIV4; 1·10 μg/mL [0·045-100] for eIIV4; and 12·6 μg/mL [1·8-100] for ccIIV4). Comparison of B-cell receptor sequencing repertoires on day 7 showed that eIIV4 increased the median frequency of canonical egg glycan-targeting B cells (0·20% [95% CI 0·067-0·37] for eIIV4; 0·058% [0·050-0·11] for RIV4; and 0·035% [0-0·062] for ccIIV4), whereas RIV4 vaccination decreased the median frequency of B-cell receptors displaying stereotypical features associated with membrane proximal anchor-targeting antibodies (0·062% [95% CI 0-0·084] for RIV4; 0·12% [0·066-0·16] for eIIV4; and 0·18% [0·016-0·20] for ccIIV4). In exploratory analysis, we characterised the structure of a highly abundant monoclonal antibody that binds to both group 1 and 2 HAs and recognises the HA trimer interface, despite its sequence resembling the stereotypical sequence motif found in membrane-proximal anchor binding antibodies. INTERPRETATION: Although all three licensed seasonal influenza vaccines elicit serological antibody repertoires with indistinguishable features shaped by heavy imprinting, the RIV4 vaccine selectively boosts higher affinity monoclonal antibodies to contemporary strains and elicits greater serum binding potency and breadth, possibly as a consequence of the multivalent structural features of the HA immunogen in this vaccine formulation. Collectively, our findings show advantages of RIV4 vaccines and more generally highlight the benefits of multivalent HA immunogens in promoting higher affinity serum antibody responses. FUNDING: Centers for Disease Control and Prevention, National Institutes of Health, and Bill & Melinda Gates Foundation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesAntibodies, ViralInfluenza, HumanImmunoglobulin GHemagglutinin Glycoproteins, Influenza VirusHumansFemaleProspective StudiesMiddle AgedAdultSeasonsProteomicsVaccinationVaccines, Inactivated

Substanzen

Influenza VaccinesAntibodies, ViralImmunoglobulin GHemagglutinin Glycoproteins, Influenza VirusVaccines, Inactivated

Autor:innen und Institutionen

  • Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA; Department of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA.
  • Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • Department of Microbiology and Immunology, Emory Vaccine Center, School of Medicine, Emory University, Atlanta, GA, USA.
  • Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Department of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA.
  • Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.

Förderung

  • NIAID NIH HHS
  • Gates Foundation
  • CDC HHS
  • National Institutes of Health
  • Bill and Melinda Gates Foundation
  • U.S. Department of Health and Human Services
  • Centers for Disease Control and Prevention
  • University of Texas at Austin

Zitieren

APA

Park, J., Bartzoka, F., von Beck, T., Li, Z. N., Mishina, M., Hebert, L. S., Kain, J., Liu, F., Sharma, S., Cao, W., Eddins, D. J., Kumar, A., Kim, J. E., Lee, J. S., Wang, Y., Schwartz, E. A., Brilot, A. F., Satterwhite, E., Towers, D. M., …, & Georgiou, G. (2025). Molecular features of the serological IgG repertoire elicited by egg-based, cell-based, or recombinant haemagglutinin-based seasonal influenza vaccines: a comparative, prospective, observational cohort study. The Lancet Microbe, 6(2), 100935. https://doi.org/10.1016/j.lanmic.2024.06.002

Vancouver

Park J, Bartzoka F, von Beck T, Li ZN, Mishina M, Hebert LS, et al. Molecular features of the serological IgG repertoire elicited by egg-based, cell-based, or recombinant haemagglutinin-based seasonal influenza vaccines: a comparative, prospective, observational cohort study. The Lancet Microbe. 2025;6(2):100935. doi:10.1016/j.lanmic.2024.06.002

BibTeX
@article{Park2025,
  author = {Park, Juyeon and Bartzoka, Foteini and von Beck, Troy and Li, Zhu-Nan and Mishina, Margarita and Hebert, Luke S and Kain, Jessica and Liu, Feng and Sharma, Suresh and Cao, Weiping and Eddins, Devon J and Kumar, Amrita and Kim, Jin Eyun and Lee, Justin S and Wang, Yuanyuan and Schwartz, Evan A and Brilot, Axel F and Satterwhite, Ed and Towers, Dalton M and McKnight, Eric and Pohl, Jan and Thompson, Mark G and Gaglani, Manjusha and Dawood, Fatimah S and Naleway, Allison L and Stevens, James and Kennedy, Richard B and Jacob, Joshy and Lavinder, Jason J and Levine, Min Z and Gangappa, Shivaprakash and Ippolito, Gregory C and Sambhara, Suryaprakash and Georgiou, George},
  title = {Molecular features of the serological IgG repertoire elicited by egg-based, cell-based, or recombinant haemagglutinin-based seasonal influenza vaccines: a comparative, prospective, observational cohort study},
  journal = {The Lancet Microbe},
  year = {2025},
  volume = {6},
  number = {2},
  pages = {100935},
  doi = {10.1016/j.lanmic.2024.06.002}
}
Kostenlos starten →